Welcome

Durata Therapeutics, established in 2009, is a clinical development stage biopharmaceutical company addressing the growing need for new therapeutics to treat infectious diseases. The Durata Vision is to become a fully integrated biopharmaceutical enterprise, focused on specialist oriented therapeutics, in areas of high unmet need, for patients with acute illness.

Durata has assembled a premier team of pharmaceutical and biopharmaceutical executives for the express purpose of acquiring, developing and commercializing novel therapeutics in the hospital and acute care settings, with particular focus on patients with infectious diseases. Our strategic intent is to create a substantial enterprise through targeted acquisition of clinical stage products, investing in high unmet need indications, streamlined development and targeting highly specialized audiences for eventual commercialization.

Durata's name was inspired by our lead product candidate, dalbavancin, which is characterized by a uniquely long "duration" of anti-bacterial activity. Dalbavancin is in late Phase-III clinical development and the Company has two antibiotic programs in earlier-stage, preclinical research. Durata is supported by a premier group of venture capital organizations – New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners.